Company / Current Liabilities
Terns Pharmaceuticals, Inc. Current Liabilities History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$15.7M
FY2024
5-year range
$6.8M / $22.8M
FY2020-FY2024
Trend
+31.0%
vs FY2023
Sector context
#195 of 214
Health Care
What the data says
Among 214 Health Care companies, Terns Pharmaceuticals, Inc. is in the top 9% for current liabilities. Current Liabilities has increased for 3 consecutive years, from $7M in FY2021 to $16M in FY2024.
Based on SEC 10-K filings.
$16M in FY2024 with a 3-year CAGR of +31.9%.
Increased from $8M to $16M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +31.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 214This company $15.7M Sector average $1.6B
▼
-99.0% below sector average
Key checks
Key Insights
- Terns Pharmaceuticals, Inc.'s current liabilities has grown for 3 consecutive years.
- 3-year CAGR of +31.9%, indicating consistent growth.
- In FY2024, current liabilities increased 31.0% year-over-year.
- Ranks #195 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 7.86 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $15.7M | +31.0% |
| FY2023 | $11.9M | +41.0% |
| FY2022 | $8.5M | +24.2% |
| FY2021 | $6.8M | -70.1% |
| FY2020 | $22.8M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026